{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["130(4)"],"submitter":["Mezquita L"],"pubmed_abstract":["<h4>Background</h4>Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAF<sup>V600E</sup>-mutant advanced non-small-cell lung cancer (NSCLC). We examined resistance to BRAF inhibition by single CTC sequencing in BRAF<sup>V600E</sup>-mutant NSCLC.<h4>Methods</h4>CTCs and cfDNA were examined in seven BRAF<sup>V600E</sup>-mutant NSCLC patients at failure to treatment. Matched tumour tissue was available for four patients. Single CTCs were isolated by fluorescence-activated cell sorting following enrichment and immunofluorescence (Hoechst 33342/CD45/pan-cytokeratins) and sequenced for mutation and copy number-alteration (CNA) analyses.<h4>Results</h4>BRAF<sup>V600E</sup> was found in 4/4 tumour biopsies and 5/7 cfDNA samples."],"journal":["British journal of cancer"],"pagination":["682-693"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10876548"],"repository":["biostudies-literature"],"pubmed_title":["Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer."],"pmcid":["PMC10876548"],"pubmed_authors":["Oulhen M","Aldea M","Honore A","Friboulet L","Mezquita L","Deloger M","Planchard D","Howarth K","Besse B","Lecluse Y","Aberlenc A","Farace F"],"additional_accession":[]},"is_claimable":false,"name":"Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.","description":"<h4>Background</h4>Resistance mechanisms to combination therapy with dabrafenib plus trametinib remain poorly understood in patients with BRAF<sup>V600E</sup>-mutant advanced non-small-cell lung cancer (NSCLC). We examined resistance to BRAF inhibition by single CTC sequencing in BRAF<sup>V600E</sup>-mutant NSCLC.<h4>Methods</h4>CTCs and cfDNA were examined in seven BRAF<sup>V600E</sup>-mutant NSCLC patients at failure to treatment. Matched tumour tissue was available for four patients. Single CTCs were isolated by fluorescence-activated cell sorting following enrichment and immunofluorescence (Hoechst 33342/CD45/pan-cytokeratins) and sequenced for mutation and copy number-alteration (CNA) analyses.<h4>Results</h4>BRAF<sup>V600E</sup> was found in 4/4 tumour biopsies and 5/7 cfDNA samples.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-04-22T11:05:49.335Z","creation":"2025-04-05T23:52:24.121Z"},"accession":"S-EPMC10876548","cross_references":{"pubmed":["38177660"],"doi":["10.1038/s41416-023-02535-0"]}}